Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Afo 150
2. Imagent
3. Imavist
4. Perfluoro-n-hexane
5. Perfluorohexane
1. Perfluorohexane
2. 355-42-0
3. Tetradecafluorohexane
4. Hexane, Tetradecafluoro-
5. Perfluoro-n-hexane
6. Flutec Pp1
7. Perfluorohexanes
8. N-tetradecafluorohexane
9. N-perfluorohexane
10. Fluorinert Fc72
11. Af0150
12. Perfluoro-compound Fc-72
13. Fluorinert Fc-72
14. 1,1,1,2,2,3,3,4,4,5,5,6,6,6-tetradecafluorohexane
15. Fluorinertr(fc-72)
16. Fx3wj41cmx
17. Chebi:39427
18. Perfluorohexane(s)
19. Af-0150
20. Fluorinert(r) Fc-72
21. Ncgc00166122-01
22. Fluorinert(tm) (fc-72)(r)
23. Hexane, 1,1,1,2,2,3,3,4,4,5,5,6,6,6-tetradecafluoro-
24. Perflexane [usan:inn]
25. Hexane, 1,1,1,2,2,3,3,4,4,5,5,6,6,6-tetradecafluoro-, Homopolymer
26. 25916-42-1
27. Einecs 206-585-0
28. Unii-fx3wj41cmx
29. Per-fluorohexane
30. Imagent?
31. Imavist?
32. Hsdb 7871
33. Fc-72
34. Mfcd00000437
35. Perflexane [usan]
36. Pp 1 (fluorocarbon)
37. Perflexane [inn]
38. N-perfluorohexane Emulsion
39. Perflexane (usan/inn)
40. Perflexane [vandf]
41. Perflexane [mart.]
42. Tetradecafluorohexane, 99%
43. Dsstox_cid_26548
44. Dsstox_rid_81709
45. Perflexane [who-dd]
46. Perflexane-lipid Microspheres
47. Perfluorohexane [mi]
48. Dsstox_gsid_46548
49. Schembl33789
50. Perfluorohexane [inci]
51. Afo145
52. Afo150
53. Chembl1200607
54. Dtxsid7046548
55. Perflexane [orange Book]
56. Fluorinert Fc72fluorinert Fc72
57. Zjijajxflbmlck-uhfffaoysa-
58. Zinc6827705
59. Tox21_112328
60. Akos005258316
61. Af 0150
62. Db09531
63. As-56640
64. Bp-21389
65. Cas-355-42-0
66. Ft-0676292
67. P0839
68. D05437
69. D92023
70. A822857
71. Q3291714
72. W-109529
73. Perfluorohexane A Mixture Of Perfluorinated Hexanes, 95%
74. Tetradecafluorohexane A Mixture Of Perfluorinated Hexanes
75. 1,1,1,2,2,3,3,4,4,5,5,6,6,6-tetradecafluorohexane #
76. Tetradecafluorohexane, A Mixture Of Perfluorinated Hexanes, 95%
| Molecular Weight | 338.04 g/mol |
|---|---|
| Molecular Formula | C6F14 |
| XLogP3 | 5.1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 3 |
| Exact Mass | 337.9776443 g/mol |
| Monoisotopic Mass | 337.9776443 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 319 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Diagnostic aid (Ultrasound contrast agent).
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1332
Imagent is an IV injected contrast echocardiography agent designed to image the left ventricle after traversing the pulmonary circulation.
PMID:16785016 Kirkton SD et al; Ultrasound in Med & Biol 32 (6): 949-59 (2006)
... Patients with varying degrees of coronary artery stenosis on quantitative angiography underwent high-mechanical-index myocardial contrast echocardiography at 15 Hz to allow measurement of phasic changes in aBV in large intramyocardial vessels using either Definity (group 1; n=22) or Imagent (group 2; n=22) ... A systolic/diastolic aBV signal ratio of >0.34 provided a sensitivity and specificity of 80% and 71%, respectively, for the detection of >75% coronary stenosis in group 1 patients, whereas a ratio of >0.43 provided a sensitivity and specificity of 89% and 74%, respectively, for the detection of >75% stenosis in group 2 patients. Both the presence and severity of a physiologically significant coronary stenosis can be detected at rest by measuring the increase in aBV on myocardial contrast echocardiography that occurs distally to the stenosis without recourse to any form of stress.
PMID:16103241 Wei K et al; Circulation 112 (8): 1154-60 (2005)
... Twelve patients /were examined. with transcranial ultrasound angiography (t USA) via the temporal bone window after an IV bolus injection of a perfluorocarbon-based microbubble contrast agent (Imagent). The aim was to display the intracranial vessel segments of the middle cerebral artery (M1, M2 and M3), the anterior cerebral artery (A1 and A2), the posterior cerebral artery (P1, P2 and P3) and the internal carotid artery (C1/2 and C3/4). t USA is a B-mode phase inversion imaging technique that uses wideband harmonic signals for image generation ... t USA provides detailed anatomical display at native B-mode spatial resolution with fewer artifacts, yielding improved delineation of intracranial vessels that are in the 1- to 2-mm range.
PMID:16085089 Holscher T et al; Ultrasound in Med & Biol 31 (8): 1001-6 (2005)
For more Therapeutic Uses (Complete) data for Perfluoro-n-hexane (16 total), please visit the HSDB record page.
The metabolism and pharmacokinetic characteristics of 1,1-dichloro-2,2,2-trifluoroethane (HCFC-123), 2-chloro-1,1,1,2-tetrafluoroethane (HCFC-124), 1-chloro-1,1-difluoroethane (HCFC-142b), and perfluorohexane (PFH) were studied in rats. The study was part of a program to investigate possible health hazards presented by candidate Halon replacements for use as a fire extinguishant. Male Fischer-344-rats and Sprague-Dawley-rats were exposed nose only to 10,000 parts per million (ppm) HCFC-123, HCFC-124, HCFC-142b, or PFH for 2 hours. Urine samples were collected for 24 hours. The rats were killed 0 or 24 hours after exposure and the tissue distribution of the compounds and their metabolites was determined by gas chromatography and fluorine-19 nuclear magnetic resonance spectroscopy. HCFC-123, HCFC-124, HCFC-142b, and PFH were detected in all tissues of rats killed immediately after exposure. ... Most tissue concentrations of the halocarbons and metabolites were below the detection limit in rats examined 24 hours post exposure. ... No PFH metabolites were detected /in urine/. ...
Dodd DE et al; Toxicology Letters 68 (1/2): 37-47 (1993)
ABOUT THIS PAGE
A Perflexane manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Perflexane, including repackagers and relabelers. The FDA regulates Perflexane manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Perflexane API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Perflexane supplier is an individual or a company that provides Perflexane active pharmaceutical ingredient (API) or Perflexane finished formulations upon request. The Perflexane suppliers may include Perflexane API manufacturers, exporters, distributors and traders.
click here to find a list of Perflexane suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Perflexane DMF (Drug Master File) is a document detailing the whole manufacturing process of Perflexane active pharmaceutical ingredient (API) in detail. Different forms of Perflexane DMFs exist exist since differing nations have different regulations, such as Perflexane USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Perflexane DMF submitted to regulatory agencies in the US is known as a USDMF. Perflexane USDMF includes data on Perflexane's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Perflexane USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Perflexane suppliers with USDMF on PharmaCompass.
Perflexane Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Perflexane GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Perflexane GMP manufacturer or Perflexane GMP API supplier for your needs.
A Perflexane CoA (Certificate of Analysis) is a formal document that attests to Perflexane's compliance with Perflexane specifications and serves as a tool for batch-level quality control.
Perflexane CoA mostly includes findings from lab analyses of a specific batch. For each Perflexane CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Perflexane may be tested according to a variety of international standards, such as European Pharmacopoeia (Perflexane EP), Perflexane JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Perflexane USP).
LOOKING FOR A SUPPLIER?
